Real-World Data Show Regorafenib on Par With TAS-102 in Metastatic CRC

A real-world comparison finds similar overall survival in patients with refractory metastatic CRC treated with either regorafenib or trifluridine/tipiracil (TAS-102).

Related Keywords

Salt Lake City ,Utah ,United States ,University Of Utah ,Christopher Nevala Plagemann ,Huntsman Cancer Institute ,Drug Administration ,Journal Of The National Comprehensive Cancer Network ,National Comprehensive Cancer Network ,Flatiron Health ,Salt Lake ,National Comprehensive Cancer ,Colorectal Cancer ,Biologic Therapy ,Toxicology ,Refractory ,Cancer ,Alignant Neoplasia ,Arcinoma ,Targeted Therapy ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Ealth And Med Tech ,Ealth And Medical Technology ,Antiangiogenesis ,Angiogenesis Inhibitor ,Evacizumab ,Nhibitor Angiogenesis ,Clinical Research ,Clinical Trials ,Linical Studies ,Humanized Monoclonal Antibody ,